MET Stock Analysis — MetLife
Sector: Financials
AI Verdict
MetLife trades at 7.9x next year's earnings while analysts expect nearly doubling EPS—this is cheap for the growth on offer, and its sticky institutional contracts make those expectations more credible than most.
Competitive Moat
MetLife is one of the largest global life insurers, with scale advantages in underwriting, distribution, and capital access that smaller rivals can't easily match. Its entrenched relationships with employers and institutions create sticky group benefits contracts that are difficult for competitors to dislodge.
Summary
MetLife is notable right now for analyst expectations of a 91.6% jump in earnings over the next year, far outpacing its sector.
Where It Stands
The stock has returned just 0.30% over the past year, trades at 7.9x forward earnings versus the sector median of 14x, and sits at a neutral RSI of 52.9.
Key Metrics
- RSI: 52.9 — Neutral
- Trailing P/E: 15.1x
- Forward P/E: 7.9x
- PEG Ratio: 0.16
- Earnings Growth: +0.9%
- Revenue Growth: +0.1%
- Market Cap: $50.4B
- Dividend Yield: 0.03%
- 1-Year Return: 0.30%
- 52-Week High: $83.85
- 52-Week Low: $67.33
Analyst Consensus
16 Buy · 6 Hold · 0 Sell (22 analysts)
Bull Case
With forward EPS growth forecast at 91.6% and a forward P/E of 7.9x, you're paying a bargain price for a potential earnings surge.
Bear Case
If the P/E reverts to the sector median of 14x after earnings normalize, the stock could see a sharp rerating down if growth disappoints or proves unsustainable.
Catalyst to Watch
Watch for the next quarterly results—if earnings growth comes in well below the 91.6% consensus, the low P/E could quickly lose its appeal.